New molecules, new IP, new opportunities. How can investors be induced to support the massive, but necessary funds required to support the important and carefully regulated research necessary to bring psychedelic therapies to market. Not to be crass, but if something isn’t going to bring a profit, it’s unlikely to receive much funding, regardless of how much good it might do, certainly not enough to cover the massive costs of bringing a disruptive therapy to market. Companies like Cybin and Bright Minds Bio are looking at modifications to create new IP, improved efficacy, and new delivery mechanisms. 

With investment validations now taken care of, we need to address issues around delivery of care. Are we prepared to shift to a model of care that moves from weekly one-hour sessions to intensive, multi-hour sessions that require new paradigms that have never been tried? Before you answer, let us ask you another question: with between 11 and 20 out of every 100 US Veterans suffering from PTSD, how can we afford not to try?

Clara Burtenshaw, co-founder of Neo Kuma Ventures created the first European Fund dedicated to psychedelics shared with us her motivations, both professional and personal, for focusing on this space. We visited with Wavepaths CEO Mendel Kaelen about their founding principles and objectives; we explore Kernel’s entre into the psychedelic research space, and we revisit Doug Drysdale, CEO of Cybin. These are the folks to watch for the future of psychedelic medicines and the healthcare revolution that is coming your way.

It has been our pleasure to bring to you this series - this passion project to understand and share the opportunities, challenges, history, and future of psychedelic medicine.

Humbly, 

Arun and JoJo

This podcast uses the following third-party services for analysis:

Podcorn - https://podcorn.com/privacy